PharmaBlock Sciences Nanjing Inc Class A Total Assets
PharmaBlock Sciences Nanjing Inc Class A total assets. Based on the latest financial reports, PharmaBlock Sciences Nanjing Inc Class A (300725) holds total assets worth CN¥5.38 Billion CNY (≈ $787.76 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see PharmaBlock Sciences Nanjing Inc Class A market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of PharmaBlock Sciences Nanjing Inc Class A (2013–2025)
Total assets of PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2025. This chart illustrates how PharmaBlock Sciences Nanjing Inc Class A's total assets have evolved over time, based on quarterly financial data. See 300725 share price today for real-time trading data and today's change.
PharmaBlock Sciences Nanjing Inc Class A - Asset Composition Analysis
PharmaBlock Sciences Nanjing Inc Class A Total Assets Breakdown (December 2025)
PharmaBlock Sciences Nanjing Inc Class A total assets breakdown as of December 2025. PharmaBlock Sciences Nanjing Inc Class A's total assets of CN¥5.38 Billion consist of 36.5% current assets and 63.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.3% |
| Accounts Receivable | CN¥381.41 Million | 5.2% |
| Inventory | CN¥655.24 Million | 8.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥103.59 Million | 1.4% |
| Goodwill | CN¥355.74 Million | 4.9% |
Asset Composition Trend (2013–2025)
This chart illustrates how PharmaBlock Sciences Nanjing Inc Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 300725 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PharmaBlock Sciences Nanjing Inc Class A's current assets represent 36.5% of total assets in 2025, a decrease from 65.7% in 2013.
- Cash Position: Cash and equivalents constituted 7.3% of total assets in 2025, down from 22.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 2.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 8.9% of total assets.
PharmaBlock Sciences Nanjing Inc Class A Competitors by Total Assets
Key competitors of PharmaBlock Sciences Nanjing Inc Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
PharmaBlock Sciences Nanjing Inc Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.94 | 3.95 | 2.29 |
| Quick Ratio | 2.95 | 2.89 | 1.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.12 Billion | CN¥2.02 Billion | CN¥1.04 Billion |
PharmaBlock Sciences Nanjing Inc Class A - Advanced Valuation Insights
This section examines the relationship between PharmaBlock Sciences Nanjing Inc Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.11 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | 48.7% |
| Total Assets | CN¥7.34 Billion |
| Market Capitalization | $1.47 Billion USD |
Valuation Analysis
Below Book Valuation: The market values PharmaBlock Sciences Nanjing Inc Class A's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: PharmaBlock Sciences Nanjing Inc Class A's assets grew by 48.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PharmaBlock Sciences Nanjing Inc Class A (2013–2025)
The table below shows the annual total assets of PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥7.34 Billion ≈ $1.07 Billion |
+48.72% |
| 2024-12-31 | CN¥4.94 Billion ≈ $722.19 Million |
-3.31% |
| 2023-12-31 | CN¥5.10 Billion ≈ $746.88 Million |
+4.97% |
| 2022-12-31 | CN¥4.86 Billion ≈ $711.49 Million |
+38.65% |
| 2021-12-31 | CN¥3.51 Billion ≈ $513.17 Million |
+44.60% |
| 2020-12-31 | CN¥2.43 Billion ≈ $354.90 Million |
+135.66% |
| 2019-12-31 | CN¥1.03 Billion ≈ $150.60 Million |
+35.21% |
| 2018-12-31 | CN¥761.16 Million ≈ $111.38 Million |
+34.15% |
| 2017-12-31 | CN¥567.40 Million ≈ $83.03 Million |
+89.67% |
| 2016-12-31 | CN¥299.15 Million ≈ $43.77 Million |
+73.44% |
| 2015-12-31 | CN¥172.48 Million ≈ $25.24 Million |
+69.83% |
| 2014-12-31 | CN¥101.56 Million ≈ $14.86 Million |
+19.30% |
| 2013-12-31 | CN¥85.13 Million ≈ $12.46 Million |
-- |
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, and mega virtual library screening to support the di… Read more